Cargando…

Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection

Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC) which are leading indications of liver transplantation (LT). To date, there is no vaccine to prevent HCV infection and LT is invariably followed by infection of the liver graft. Within th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeisel, Mirjam B., Crouchet, Emilie, Baumert, Thomas F., Schuster, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664971/ https://www.ncbi.nlm.nih.gov/pubmed/26540069 http://dx.doi.org/10.3390/v7112898

Ejemplares similares

Host-targeting therapies for hepatitis C virus infection: current developments and future applications
por: Crouchet, Emilie, et al.
Publicado: (2018)

Hepatitis C Virus (HCV)–Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design
por: Wrensch, Florian, et al.
Publicado: (2018)

Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes
por: Verrier, Eloi R., et al.
Publicado: (2016)

Composite vector formulation for multiple siRNA delivery as a host targeting antiviral in a cell culture model of hepatitis C virus (HCV) infection†
por: Crouchet, E., et al.
Publicado: (2017)

Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection
por: Verrier, Eloi R., et al.
Publicado: (2016)

CD81-Receptor Associations — Impact for Hepatitis C Virus Entry and Antiviral Therapies
por: Zona, Laetitia, et al.
Publicado: (2014)

Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets
por: Verrier, Eloi R, et al.
Publicado: (2020)

Liver cell circuits and therapeutic discovery for advanced liver disease and cancer
por: Crouchet, Emilie, et al.
Publicado: (2021)

Hepatitis C virus infection and related liver disease: the quest for the best animal model
por: Mailly, Laurent, et al.
Publicado: (2013)

Hepatitis B virus–host interactions and novel targets for viral cure
por: Ligat, Gaëtan, et al.
Publicado: (2021)

Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection
por: Fafi-Kremer, Samira, et al.
Publicado: (2012)

Adaptive Immunity to Hepatitis C Virus
por: Zeisel, Mirjam B., et al.
Publicado: (2009)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma
por: Zeisel, Mirjam B., et al.
Publicado: (2021)

Targeting the Host for New Therapeutic Perspectives in Hepatitis D
por: Turon-Lagot, Vincent, et al.
Publicado: (2020)

Hepatitis B virus compartmentalization and single-cell differentiation in hepatocellular carcinoma
por: Jühling, Frank, et al.
Publicado: (2021)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors
por: Bitzegeio, Julia, et al.
Publicado: (2010)

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
por: Roehlen, Natascha, et al.
Publicado: (2020)

Hepatitis C Virus Entry: An Intriguingly Complex and Highly Regulated Process
por: Colpitts, Che C., et al.
Publicado: (2020)

Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma
por: Plissonnier, Marie-Laure, et al.
Publicado: (2018)

New perspectives for preventing hepatitis C virus liver graft infection
por: Felmlee, Daniel J., et al.
Publicado: (2016)

Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma
por: Baumert, Thomas F., et al.
Publicado: (2019)

The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression
por: Wolf, Marie, et al.
Publicado: (2008)

Targeting Viral cccDNA for Cure of Chronic Hepatitis B
por: Ligat, Gaëtan, et al.
Publicado: (2020)

A Novel Monoclonal Anti-CD81 Antibody Produced by Genetic Immunization Efficiently Inhibits Hepatitis C Virus Cell-Cell Transmission
por: Fofana, Isabel, et al.
Publicado: (2013)

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
por: Xiao, Fei, et al.
Publicado: (2015)

Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease
por: Felmlee, Daniel J., et al.
Publicado: (2013)

Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral Response Assessed through Optimal Covariance Networks
por: Murray, John M., et al.
Publicado: (2013)

Boceprevir and personalized medicine in hepatitis C virus infection
por: Habersetzer, François, et al.
Publicado: (2012)

Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip
por: Goto, Kaku, et al.
Publicado: (2020)

Signalome-wide assessment of host cell response to hepatitis C virus
por: Haqshenas, Gholamreza, et al.
Publicado: (2017)

Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus
por: Liu, Dandan, et al.
Publicado: (2023)

Clearance of persistent hepatitis C virus infection using a claudin-1-targeting monoclonal antibody
por: Mailly, Laurent, et al.
Publicado: (2015)

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence
por: Ke, Ruian, et al.
Publicado: (2018)

Hepatitis B Virus Cure: Targets and Future Therapies
por: Lee, Hye Won, et al.
Publicado: (2020)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

What are the pros and cons of the use of host-targeted agents against hepatitis C?
por: Pawlotsky, Jean-Michel
Publicado: (2014)

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
por: Marascio, Nadia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iknd9onia4lg3ipdr80r8qsa2u